Advanced Oncotherapy – Additional Director Dealing

Advanced Oncotherapy (AVO) announces that Michael Sinclair, Executive Chairman of the Company, on 18 December 2015 purchased 500,000 ordinary shares of 1 penny each in the Company at 6.25 pence per Ordinary Share. The Company also announces that Fairford Capital Ltd, of which Michael Bradfield, a Non-Executive Director of the Company, is the sole beneficial owner, […]

Advanced Oncotherapy – Director Dealing & Total Voting Rights

Advanced Oncotherapy (AVO), the developer of next-generation proton therapy systems for cancer treatment, has been informed that Michael Sinclair, Executive Chairman of the Company, has yesterday sold 7 million ordinary shares of 1 penny each in the Company at 8.25 pence per Share in order to fund the exercise of warrants over 28.5 million Shares […]

Advanced Oncotherapy – Director Dealing

Advanced Oncotherapy announces that Michael Sinclair, Executive Chairman of the Company, had yesterday purchased an option over 30 million ordinary shares of 1 penny each in the Company from Brahma AG at a cost of £300,000. The Option vests immediately, expires two years from today’s date and has an exercise price of 10p per Ordinary Share. […]